These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

234 related items for PubMed ID: 6180622

  • 1. Long-term survival of patients with malignant ventricular arrhythmia treated with antiarrhythmic drugs.
    Graboys TB, Lown B, Podrid PJ, DeSilva R.
    Am J Cardiol; 1982 Sep; 50(3):437-43. PubMed ID: 6180622
    [Abstract] [Full Text] [Related]

  • 2. Determinants of survival in patients with malignant ventricular arrhythmia associated with coronary artery disease.
    Lampert S, Lown B, Graboys TB, Podrid PJ, Blatt CM.
    Am J Cardiol; 1988 Apr 01; 61(10):791-7. PubMed ID: 3354443
    [Abstract] [Full Text] [Related]

  • 3. Prognosis of patients with ventricular tachycardia or fibrillation and a normal electrophysiologic study.
    Kim SG, Aboaf AP, Roth J, Ferrick K, Fisher JD.
    Am Heart J; 1991 Jan 01; 121(1 Pt 1):77-80. PubMed ID: 1985381
    [Abstract] [Full Text] [Related]

  • 4. Management of patients at high risk of sudden death.
    Lown B.
    Am Heart J; 1982 Apr 01; 103(4 Pt 2):689-97. PubMed ID: 6175197
    [Abstract] [Full Text] [Related]

  • 5. [Can sudden cardiac death be prevented by treatment with anti-arrhythmia drugs?].
    Zrenner B, Koller B, Rudolph W.
    Herz; 1990 Apr 01; 15(2):90-102. PubMed ID: 2188895
    [Abstract] [Full Text] [Related]

  • 6. Ventricular arrhythmias in severe heart failure: incidence, significance, and effectiveness of antiarrhythmic therapy.
    Chakko CS, Gheorghiade M.
    Am Heart J; 1985 Mar 01; 109(3 Pt 1):497-504. PubMed ID: 3976476
    [Abstract] [Full Text] [Related]

  • 7. [New aspects of the clinical use of anti-arrhythmia agents with special reference to acute therapy of ventricular tachycardia (lidocaine vs. ajmaline)].
    Manz M, Mletzko R, Jung W, Lüderitz B.
    Herz; 1990 Apr 01; 15(2):79-89. PubMed ID: 2188894
    [Abstract] [Full Text] [Related]

  • 8. [Value of experimental and clinical methods on the effectiveness and side effect profile of anti-arrhythmia agents].
    Kuck KH.
    Z Kardiol; 1992 Apr 01; 81 Suppl 4():151-5. PubMed ID: 1283932
    [Abstract] [Full Text] [Related]

  • 9. [Causes and treatment of ventricular arrhythmias].
    Kappenberger L.
    Schweiz Med Wochenschr; 1990 Jun 23; 120(25):941-5. PubMed ID: 1695020
    [Abstract] [Full Text] [Related]

  • 10. Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias.
    Borggrefe M, Trampisch HJ, Breithardt G.
    J Am Coll Cardiol; 1988 Jul 23; 12(1):140-9. PubMed ID: 3379199
    [Abstract] [Full Text] [Related]

  • 11. [Detection of patients at risk for sudden heart death by long-term ECG. The role of life-threatening ventricular arrhythmias].
    Hombach V, Höpp HW, Osterspey A, Winter U, Deutsch H, Hilger HH.
    Herz; 1984 Feb 23; 9(1):6-25. PubMed ID: 6200415
    [Abstract] [Full Text] [Related]

  • 12. Use of nonsustained ventricular tachycardia as a guide to antiarrhythmic drug therapy in patients with malignant ventricular arrhythmia.
    Podrid PJ, Schoeneberger A, Lown B, Lampert S, Matos J, Porterfield J, Raeder E, Corrigan E.
    Am Heart J; 1983 Feb 23; 105(2):181-8. PubMed ID: 6823797
    [Abstract] [Full Text] [Related]

  • 13. [Arrhythmias in hypertrophic cardiomyopathy. Significance and therapeutic consequences].
    McKenna WJ, Kleinebenne A.
    Herz; 1985 Apr 23; 10(2):91-101. PubMed ID: 2580767
    [Abstract] [Full Text] [Related]

  • 14. Predictors of antiarrhythmic drug efficacy in patients with malignant ventricular tachyarrhythmias.
    Hohnloser SH, Raeder EA, Podrid PJ, Graboys TB, Lown B.
    Am Heart J; 1987 Jul 23; 114(1 Pt 1):1-7. PubMed ID: 3604854
    [Abstract] [Full Text] [Related]

  • 15. [Arrhythmia and anti-arrhythmia therapy as prognostic risks].
    Meinertz T, Zehender M, Hofmann T, Hohnloser S, Just H.
    Herz; 1991 Sep 23; 16 Spec No 1():314-7, 323. PubMed ID: 1820298
    [Abstract] [Full Text] [Related]

  • 16. Can antiarrhythmic drugs survive survival trials?
    Pratt CM, Waldo AL, Camm AJ.
    Am J Cardiol; 1998 Mar 19; 81(6A):24D-34D. PubMed ID: 9537220
    [Abstract] [Full Text] [Related]

  • 17. Combination antiarrhythmic therapy for management of malignant ventricular arrhythmia.
    Patt MV, Grossbard CL, Graboys TB, Lown B.
    Am J Cardiol; 1988 Nov 03; 62(14):18I-21I. PubMed ID: 2461071
    [Abstract] [Full Text] [Related]

  • 18. Nonsustained ventricular tachycardia as a predictor for sudden death in patients with idiopathic dilated cardiomyopathy. The role of amiodarone treatment.
    Castelli G, Ciaccheri M, Cecchi F, Troiani V, Nannini M, Marconi P, Olivotto J, Montereggi A, Dolara A.
    G Ital Cardiol; 1999 May 03; 29(5):514-23. PubMed ID: 10367218
    [Abstract] [Full Text] [Related]

  • 19. A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias.
    Antiarrhythmics versus Implantable Defibrillators (AVID) Investigators.
    N Engl J Med; 1997 Nov 27; 337(22):1576-83. PubMed ID: 9411221
    [Abstract] [Full Text] [Related]

  • 20. Is programmed stimulation of value in predicting the long-term success of antiarrhythmic therapy for ventricular tachycardias?
    Kim SG, Seiden SW, Felder SD, Waspe LE, Fisher JD.
    N Engl J Med; 1986 Aug 07; 315(6):356-62. PubMed ID: 2426592
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.